Portfolio Holdings Detail for ISIN IE00BFNM3H51
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares MSCI USA ESG Screened UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker SDUS(USD) LSE
ETF Ticker SLUS(EUR) F
ETF Ticker SDUS.LS(USD) CXE
ETF Ticker SLUS.DE(EUR) CXE
ETF Ticker SDUS.L(GBP) LSE

Holdings detail for REGN

Stock Name	Regeneron Pharmaceuticals Inc
Ticker	REGN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US75886F1075
LEI	549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria: (RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages: Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL: Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors: Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN: In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC: Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.: Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.: D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares MSCI USA ESG Screened UCITS ETF USD (Dist) REGN holdings

Date	Number of REGN Shares Held	Base Market Value of REGN Shares	Local Market Value of REGN Shares	Change in REGN Shares Held	Change in REGN Base Value	Current Price per REGN Share Held	Previous Price per REGN Share Held
2025-09-29 (Monday)	32,137	USD 18,020,823	USD 18,020,823
2025-09-26 (Friday)	32,004	USD 18,047,056	USD 18,047,056
2025-09-25 (Thursday)	31,703	USD 17,611,334	USD 17,611,334	21	USD -668,546	USD 555.51	USD 576.98
2025-09-24 (Wednesday)	31,682	USD 18,279,880	USD 18,279,880
2025-09-18 (Thursday)	31,283	USD 18,729,445	USD 18,729,445	84	USD 462,430	USD 598.71	USD 585.5
2025-09-17 (Wednesday)	31,199	USD 18,267,015	USD 18,267,015	105	USD 386,099	USD 585.5	USD 575.06
2025-09-16 (Tuesday)	31,094	USD 17,880,916	USD 17,880,916	168	USD 172,998	USD 575.06	USD 572.59
2025-09-15 (Monday)	30,926	USD 17,707,918	USD 17,707,918
2025-09-12 (Friday)	30,870	USD 17,287,200	USD 17,287,200

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00BFNM3H51

Show aggregate share trades of REGN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-09-25 BUY 21 555.510* 668.75
2025-09-18 BUY 84 598.710* 669.13
2025-09-17 BUY 105 585.500* 669.59
2025-09-16 BUY 168 575.060* 670.11
2025-08-15 BUY 14 580.410* 671.15
2025-08-13 BUY 7 561.550* 671.77
2025-08-08 BUY 62 563.000* 673.04
2025-08-06 BUY 131 555.130* 674.37
2025-07-31 BUY 35 545.460* 675.72
2025-07-29 BUY 140 558.145* 677.13
2025-07-11 BUY 56 567.740* 677.77
2025-07-10 BUY 63 559.760* 678.48
2025-07-09 BUY 63 552.580* 679.23
2025-07-07 SELL -42 538.110* 680.88 Profit of 28,597 on sale
2025-07-02 SELL -175 547.740* 683.35 Profit of 119,587 on sale
2025-06-27 BUY 21 521.000* 685.36
2025-06-26 BUY 21 521.000* 686.39
2025-06-24 SELL -98 522.270* 688.49 Profit of 67,472 on sale
2025-06-18 BUY 56 513.580* 693.10
2025-06-17 BUY 21 508.860* 694.32
2025-06-16 SELL -29 522.680* 695.45 Profit of 20,168 on sale
2025-06-12 SELL -35 521.840* 696.61 Profit of 24,381 on sale
2025-06-11 BUY 77 518.600* 697.80
2025-06-06 BUY 21 493.220* 701.63
2025-06-05 BUY 98 483.070* 703.14
2025-06-04 BUY 14 484.930* 704.66
2025-06-03 SELL -7 487.860* 706.17 Profit of 4,943 on sale
2025-05-30 SELL -854 490.280* 709.23 Profit of 605,683 on sale
2025-05-29 BUY 17 605.390* 709.97
2025-05-27 BUY 119 603.260* 711.60
2025-05-23 BUY 90 588.340* 713.41
2025-05-22 BUY 49 596.850* 714.28
2025-05-19 BUY 42 596.540* 716.75
2025-05-16 BUY 21 594.320* 717.69
2025-05-15 SELL -14 584.990* 718.71 Profit of 10,062 on sale
2025-05-14 BUY 7 571.360* 719.85
2025-05-13 BUY 14 574.160* 720.99
2025-05-12 BUY 49 575.630* 722.13
2025-05-09 SELL -35 527.780* 723.68 Profit of 25,329 on sale
2025-05-08 BUY 14 547.670* 725.09
2025-05-07 BUY 21 560.930* 726.41
2025-05-02 BUY 777 605.610* 729.81
2025-04-30 BUY 245 598.760* 732.09
2025-04-29 BUY 60 568.910* 733.47
2025-04-28 BUY 49 610.860* 734.52
2025-04-25 BUY 126 602.640* 735.65
2025-04-24 SELL -147 599.760* 736.84 Profit of 108,315 on sale
2025-04-23 BUY 133 587.850* 738.14
2025-04-22 BUY 56 585.490* 739.49
2025-04-17 BUY 77 563.160* 744.32
2025-04-15 BUY 70 557.910* 747.85
2025-04-11 BUY 112 554.180* 751.34
2025-04-09 BUY 42 576.720* 754.99
2025-04-08 BUY 252 556.810* 756.92
2025-04-07 BUY 81 572.780* 758.72
2025-04-04 SELL -112 573.450* 760.56 Profit of 85,183 on sale
2025-04-02 BUY 952 625.600* 761.91
2025-04-01 BUY 7 617.000* 763.37
2025-03-31 BUY 49 634.230* 764.69
2025-03-28 BUY 28 637.360* 766.00
2025-03-27 BUY 12 635.830* 767.36
2025-03-26 BUY 7 640.140* 768.70
2025-03-25 BUY 75 634.140* 770.13
2025-03-24 BUY 78 661.000* 771.30
2025-03-21 SELL -28 658.480* 772.53 Profit of 21,631 on sale
2025-03-20 BUY 112 662.620* 773.74
2025-03-19 BUY 18 672.360* 774.86
2025-03-18 BUY 232 664.960* 776.10
2025-03-17 BUY 49 678.420* 777.21
2025-03-14 BUY 364 666.870* 778.48
2025-03-13 BUY 70 680.610* 779.61
2025-03-12 SELL -350 689.500* 780.67 Profit of 273,236 on sale
2025-03-11 SELL -259 718.160* 781.42 Profit of 202,387 on sale
2025-03-10 BUY 77 744.830* 781.86
2025-03-07 BUY 14 707.510* 782.77
2025-03-05 BUY 105 687.150* 783.95
2025-03-04 BUY 119 675.490* 785.30
2025-03-03 BUY 224 684.870* 786.57
2025-02-28 BUY 182 698.740* 787.70
2025-02-27 SELL -35 702.780* 788.80 Profit of 27,608 on sale
2025-02-25 BUY 259 723.470* 790.76
2025-02-21 BUY 28 700.330* 793.06
2025-02-18 SELL -63 680.000* 797.60 Profit of 50,249 on sale
2025-02-14 SELL -427 673.600* 801.25 Profit of 342,133 on sale
2025-02-13 BUY 7 674.270* 803.14
2025-02-12 BUY 68 663.860* 805.25
2025-02-07 SELL -12 710.000* 810.81 Profit of 9,730 on sale
2025-02-06 BUY 133 722.070* 812.24
2025-02-05 BUY 35 716.720* 813.81
2025-02-04 BUY 42 697.050* 815.75
2025-02-03 BUY 42 666.850* 818.27
2025-01-31 BUY 77 672.980* 820.78
2025-01-29 SELL -7 687.270* 825.62 Profit of 5,779 on sale
2025-01-28 SELL -63 686.330* 828.16 Profit of 52,174 on sale
2025-01-27 SELL -112 684.710* 830.81 Profit of 93,051 on sale
2025-01-24 BUY 84 675.790* 833.74
2025-01-23 BUY 14 694.640* 836.41
2024-12-10 BUY 350 778.500* 837.55
2024-12-09 BUY 42 788.000* 838.54
2024-12-06 SELL -105 778.000* 839.77 Profit of 88,176 on sale
2024-12-05 SELL -7 767.900* 841.27 Profit of 5,889 on sale
2024-12-03 BUY 35 749.570* 845.16
2024-11-27 SELL -42 754.870* 853.69 Profit of 35,855 on sale
2024-11-26 BUY 147 753.030* 858.72
2024-11-26 BUY 147 753.030* 858.72
2024-11-25 BUY 17 749.510* 864.47
2024-11-25 BUY 17 749.510* 864.47
2024-11-22 SELL -12 738.000* 867.89 Profit of 10,415 on sale
2024-11-21 SELL -35 744.500* 871.31 Profit of 30,496 on sale
2024-11-20 SELL -14 743.350* 874.97 Profit of 12,250 on sale
2024-11-19 BUY 7 744.600* 878.80
2024-11-18 BUY 60 762.000* 882.34
2024-11-11 BUY 21 825.680* 888.17
2024-11-11 BUY 21 825.680* 888.17
2024-11-07 BUY 17 824.480* 897.66
2024-11-07 BUY 17 824.480* 897.66
2024-11-06 BUY 168 816.650* 904.41
2024-11-06 BUY 168 816.650* 904.41
2024-11-05 BUY 35 829.430* 911.23
2024-11-05 BUY 35 829.430* 911.23
2024-11-04 BUY 12 828.840* 919.47
2024-11-04 BUY 12 828.840* 919.47
2024-11-01 BUY 18 843.600* 927.90
2024-11-01 BUY 18 843.600* 927.90
2024-10-30 SELL -42 922.790* 941.44 Profit of 39,541 on sale
2024-10-30 SELL -42 922.790* 941.44 Profit of 39,541 on sale
2024-10-29 SELL -126 927.330* 943.79 Profit of 118,918 on sale
2024-10-29 SELL -126 927.330* 943.79 Profit of 118,918 on sale
2024-10-28 SELL -49 928.610* 946.83 Profit of 46,395 on sale
2024-10-28 SELL -49 928.610* 946.83 Profit of 46,395 on sale
2024-10-21 SELL -7 968.500* 0.00
2024-10-21 SELL -7 968.500* 0.00
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-09-25	BUY	21	555.510*	668.75
2025-09-18	BUY	84	598.710*	669.13
2025-09-17	BUY	105	585.500*	669.59
2025-09-16	BUY	168	575.060*	670.11
2025-08-15	BUY	14	580.410*	671.15
2025-08-13	BUY	7	561.550*	671.77
2025-08-08	BUY	62	563.000*	673.04
2025-08-06	BUY	131	555.130*	674.37
2025-07-31	BUY	35	545.460*	675.72
2025-07-29	BUY	140	558.145*	677.13
2025-07-11	BUY	56	567.740*	677.77
2025-07-10	BUY	63	559.760*	678.48
2025-07-09	BUY	63	552.580*	679.23
2025-07-07	SELL	-42	538.110*	680.88 Profit of 28,597 on sale
2025-07-02	SELL	-175	547.740*	683.35 Profit of 119,587 on sale
2025-06-27	BUY	21	521.000*	685.36
2025-06-26	BUY	21	521.000*	686.39
2025-06-24	SELL	-98	522.270*	688.49 Profit of 67,472 on sale
2025-06-18	BUY	56	513.580*	693.10
2025-06-17	BUY	21	508.860*	694.32
2025-06-16	SELL	-29	522.680*	695.45 Profit of 20,168 on sale
2025-06-12	SELL	-35	521.840*	696.61 Profit of 24,381 on sale
2025-06-11	BUY	77	518.600*	697.80
2025-06-06	BUY	21	493.220*	701.63
2025-06-05	BUY	98	483.070*	703.14
2025-06-04	BUY	14	484.930*	704.66
2025-06-03	SELL	-7	487.860*	706.17 Profit of 4,943 on sale
2025-05-30	SELL	-854	490.280*	709.23 Profit of 605,683 on sale
2025-05-29	BUY	17	605.390*	709.97
2025-05-27	BUY	119	603.260*	711.60
2025-05-23	BUY	90	588.340*	713.41
2025-05-22	BUY	49	596.850*	714.28
2025-05-19	BUY	42	596.540*	716.75
2025-05-16	BUY	21	594.320*	717.69
2025-05-15	SELL	-14	584.990*	718.71 Profit of 10,062 on sale
2025-05-14	BUY	7	571.360*	719.85
2025-05-13	BUY	14	574.160*	720.99
2025-05-12	BUY	49	575.630*	722.13
2025-05-09	SELL	-35	527.780*	723.68 Profit of 25,329 on sale
2025-05-08	BUY	14	547.670*	725.09
2025-05-07	BUY	21	560.930*	726.41
2025-05-02	BUY	777	605.610*	729.81
2025-04-30	BUY	245	598.760*	732.09
2025-04-29	BUY	60	568.910*	733.47
2025-04-28	BUY	49	610.860*	734.52
2025-04-25	BUY	126	602.640*	735.65
2025-04-24	SELL	-147	599.760*	736.84 Profit of 108,315 on sale
2025-04-23	BUY	133	587.850*	738.14
2025-04-22	BUY	56	585.490*	739.49
2025-04-17	BUY	77	563.160*	744.32
2025-04-15	BUY	70	557.910*	747.85
2025-04-11	BUY	112	554.180*	751.34
2025-04-09	BUY	42	576.720*	754.99
2025-04-08	BUY	252	556.810*	756.92
2025-04-07	BUY	81	572.780*	758.72
2025-04-04	SELL	-112	573.450*	760.56 Profit of 85,183 on sale
2025-04-02	BUY	952	625.600*	761.91
2025-04-01	BUY	7	617.000*	763.37
2025-03-31	BUY	49	634.230*	764.69
2025-03-28	BUY	28	637.360*	766.00
2025-03-27	BUY	12	635.830*	767.36
2025-03-26	BUY	7	640.140*	768.70
2025-03-25	BUY	75	634.140*	770.13
2025-03-24	BUY	78	661.000*	771.30
2025-03-21	SELL	-28	658.480*	772.53 Profit of 21,631 on sale
2025-03-20	BUY	112	662.620*	773.74
2025-03-19	BUY	18	672.360*	774.86
2025-03-18	BUY	232	664.960*	776.10
2025-03-17	BUY	49	678.420*	777.21
2025-03-14	BUY	364	666.870*	778.48
2025-03-13	BUY	70	680.610*	779.61
2025-03-12	SELL	-350	689.500*	780.67 Profit of 273,236 on sale
2025-03-11	SELL	-259	718.160*	781.42 Profit of 202,387 on sale
2025-03-10	BUY	77	744.830*	781.86
2025-03-07	BUY	14	707.510*	782.77
2025-03-05	BUY	105	687.150*	783.95
2025-03-04	BUY	119	675.490*	785.30
2025-03-03	BUY	224	684.870*	786.57
2025-02-28	BUY	182	698.740*	787.70
2025-02-27	SELL	-35	702.780*	788.80 Profit of 27,608 on sale
2025-02-25	BUY	259	723.470*	790.76
2025-02-21	BUY	28	700.330*	793.06
2025-02-18	SELL	-63	680.000*	797.60 Profit of 50,249 on sale
2025-02-14	SELL	-427	673.600*	801.25 Profit of 342,133 on sale
2025-02-13	BUY	7	674.270*	803.14
2025-02-12	BUY	68	663.860*	805.25
2025-02-07	SELL	-12	710.000*	810.81 Profit of 9,730 on sale
2025-02-06	BUY	133	722.070*	812.24
2025-02-05	BUY	35	716.720*	813.81
2025-02-04	BUY	42	697.050*	815.75
2025-02-03	BUY	42	666.850*	818.27
2025-01-31	BUY	77	672.980*	820.78
2025-01-29	SELL	-7	687.270*	825.62 Profit of 5,779 on sale
2025-01-28	SELL	-63	686.330*	828.16 Profit of 52,174 on sale
2025-01-27	SELL	-112	684.710*	830.81 Profit of 93,051 on sale
2025-01-24	BUY	84	675.790*	833.74
2025-01-23	BUY	14	694.640*	836.41
2024-12-10	BUY	350	778.500*	837.55
2024-12-09	BUY	42	788.000*	838.54
2024-12-06	SELL	-105	778.000*	839.77 Profit of 88,176 on sale
2024-12-05	SELL	-7	767.900*	841.27 Profit of 5,889 on sale
2024-12-03	BUY	35	749.570*	845.16
2024-11-27	SELL	-42	754.870*	853.69 Profit of 35,855 on sale
2024-11-26	BUY	147	753.030*	858.72
2024-11-26	BUY	147	753.030*	858.72
2024-11-25	BUY	17	749.510*	864.47
2024-11-25	BUY	17	749.510*	864.47
2024-11-22	SELL	-12	738.000*	867.89 Profit of 10,415 on sale
2024-11-21	SELL	-35	744.500*	871.31 Profit of 30,496 on sale
2024-11-20	SELL	-14	743.350*	874.97 Profit of 12,250 on sale
2024-11-19	BUY	7	744.600*	878.80
2024-11-18	BUY	60	762.000*	882.34
2024-11-11	BUY	21	825.680*	888.17
2024-11-11	BUY	21	825.680*	888.17
2024-11-07	BUY	17	824.480*	897.66
2024-11-07	BUY	17	824.480*	897.66
2024-11-06	BUY	168	816.650*	904.41
2024-11-06	BUY	168	816.650*	904.41
2024-11-05	BUY	35	829.430*	911.23
2024-11-05	BUY	35	829.430*	911.23
2024-11-04	BUY	12	828.840*	919.47
2024-11-04	BUY	12	828.840*	919.47
2024-11-01	BUY	18	843.600*	927.90
2024-11-01	BUY	18	843.600*	927.90
2024-10-30	SELL	-42	922.790*	941.44 Profit of 39,541 on sale
2024-10-30	SELL	-42	922.790*	941.44 Profit of 39,541 on sale
2024-10-29	SELL	-126	927.330*	943.79 Profit of 118,918 on sale
2024-10-29	SELL	-126	927.330*	943.79 Profit of 118,918 on sale
2024-10-28	SELL	-49	928.610*	946.83 Profit of 46,395 on sale
2024-10-28	SELL	-49	928.610*	946.83 Profit of 46,395 on sale
2024-10-21	SELL	-7	968.500*	0.00
2024-10-21	SELL	-7	968.500*	0.00

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	208,659	1,635	312,812	66.7%
2025-09-18	236,485	3,679	387,519	61.0%
2025-09-17	229,191	716	370,895	61.8%
2025-09-16	173,632	584	271,020	64.1%
2025-09-15	204,491	251	334,496	61.1%
2025-09-12	117,504	33	222,760	52.7%
2025-09-11	125,478	3,137	286,516	43.8%
2025-09-10	195,068	481	339,885	57.4%
2025-09-09	129,168	994	274,520	47.1%
2025-09-08	250,895	396	527,062	47.6%
2025-09-05	170,149	290	289,566	58.8%
2025-09-04	188,227	2,103	360,619	52.2%
2025-09-03	185,679	344	438,111	42.4%
2025-09-02	191,954	138	476,288	40.3%
2025-08-29	133,226	685	236,726	56.3%
2025-08-28	116,560	2,177	256,675	45.4%
2025-08-27	113,719	465	243,836	46.6%
2025-08-26	210,376	450	400,199	52.6%
2025-08-25	149,130	68	363,377	41.0%
2025-08-22	211,822	3,244	701,770	30.2%
2025-08-21	257,492	3,416	446,439	57.7%
2025-08-20	327,738	572	559,133	58.6%
2025-08-19	118,472	2,191	324,311	36.5%
2025-08-18	146,282	388	277,909	52.6%
2025-08-15	209,923	3,375	441,752	47.5%
2025-08-14	157,569	3,623	429,327	36.7%
2025-08-13	111,342	233	362,786	30.7%
2025-08-12	117,647	171	310,775	37.9%
2025-08-11	129,513	2,676	284,757	45.5%
2025-08-08	128,559	1,038	431,841	29.8%
2025-08-07	166,648	1,560	352,877	47.2%
2025-08-06	176,311	624	397,089	44.4%
2025-08-05	154,257	115	353,744	43.6%
2025-08-04	200,758	1,913	409,897	49.0%
2025-08-01	349,775	3,745	728,720	48.0%
2025-07-31	222,350	476	549,344	40.5%
2025-07-30	106,839	1,689	231,761	46.1%
2025-07-29	149,359	276	292,667	51.0%
2025-07-28	103,687	1,380	245,287	42.3%
2025-07-25	103,783	556	259,069	40.1%
2025-07-24	156,974	2,397	291,677	53.8%
2025-07-23	168,734	1,708	355,372	47.5%
2025-07-22	116,324	617	304,880	38.2%
2025-07-21	98,482	900	250,107	39.4%
2025-07-18	183,174	1,051	391,909	46.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares MSCI USA ESG Screened UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	SDUS(USD) LSE
ETF Ticker	SLUS(EUR) F
ETF Ticker	SDUS.LS(USD) CXE
ETF Ticker	SLUS.DE(EUR) CXE
ETF Ticker	SDUS.L(GBP) LSE